Laroprovstat Dose X STP
Phase 1Small molecule
AstraZenecaLaroprovstat Dose X STP is one of 11 small molecule programs targeting Statin. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Statin
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Combination Therapy
Chong Kun Dang PharmaceuticalPhase 3
Somatostatin Analog
UUniversity of Aarhus
Phase 3
Intensive Statin Treatment
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
Octreotide
Johnson & JohnsonPreclinical
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 1
Laroprovstat Dose X STP
AstraZenecaPhase 1
Bryostatin 1
NNational Cancer Institute (NCI)
Phase 1
Test Drug
Chong Kun Dang PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Laroprovstat Dose X STP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company